Monkeypox (Mpox) Testing & Treatment Springfield Lakes: Complete Guide 2025

Concerned about monkeypox exposure? Monkeypox (mpox) is a viral infection that can be transmitted through close contact, including sexual contact. Early recognition, testing, and appropriate management are crucial for individual health and preventing transmission.

Understanding Monkeypox (Mpox)

Monkeypox is a viral infection caused by the monkeypox virus, a member of the orthopoxvirus family. The disease was renamed “mpox” by the World Health Organization in 2022 to reduce stigma and discrimination associated with the previous name.

Global Outbreak and Australian Response

Epidemiological Data	Global Statistics	Australian Context
2022-2023 Outbreak	90,000+ cases globally	300+ confirmed cases
Primary Demographics	95% men who have sex with men	Similar pattern
Transmission Pattern	Close/intimate contact	Sexual networks
Case Fatality Rate	<1% (developed countries)	No deaths in Australia

Virus Characteristics

Monkeypox Virus:

Family – Orthopoxvirus (related to smallpox)
Genome – Double-stranded DNA virus
Stability – Stable in environment for weeks
Clades – West African (current outbreak) and Central African

Transmission Characteristics:

Infectious period – From symptom onset until scabs heal
Viral shedding – Skin lesions, respiratory secretions
Environmental stability – Survives on surfaces
Zoonotic potential – Animal-to-human transmission

Transmission and Risk Factors

Modes of Transmission

Transmission Route	Mechanism	Risk Level	Prevention
Close skin contact	Direct contact with lesions	High	Avoid contact with lesions
Sexual contact	Genital, anal, oral contact	High	Barrier protection
Respiratory droplets	Prolonged face-to-face contact	Moderate	Mask use, distance
Contaminated materials	Bedding, clothing, surfaces	Low-moderate	Proper hygiene
Vertical transmission	Mother to fetus	Possible	Pregnancy monitoring

High-Risk Populations

Current Outbreak:

Men who have sex with men – 95% of cases
Multiple sexual partners – increased exposure risk
Anonymous sexual encounters – contact tracing challenges
Commercial sex workers – occupational exposure
Close household contacts – family transmission

Occupational Risk:

Healthcare workers – patient care exposure
Laboratory personnel – specimen handling
Animal handlers – zoonotic exposure (rare)
Cleaning staff – contaminated environment

Clinical Presentation

Incubation Period and Phases

Phase	Timeline	Characteristics	Infectivity
Incubation	6-13 days (range 5-21)	Asymptomatic	Not infectious
Prodromal	1-3 days	Fever, malaise, lymphadenopathy	Possibly infectious
Rash phase	14-28 days	Characteristic lesions	Highly infectious
Recovery	Variable	Scab formation, healing	Infectious until scabs fall off

Clinical Features

Prodromal Symptoms (before rash):

Fever – 38.5°C or higher (85% of cases)
Lymphadenopathy – enlarged lymph nodes (75%)
Headache – moderate to severe (70%)
Muscle aches – myalgia (65%)
Fatigue – extreme tiredness (60%)
Chills – with fever (50%)

Rash Characteristics:

Evolution – macules → papules → vesicles → pustules → scabs
Distribution – often genital/perianal in current outbreak
Number – 1-100+ lesions (median 10-20)
Appearance – well-circumscribed, deep-seated
Progression – all lesions in same stage of development

Atypical Presentations

2022-2023 Outbreak Variations:

Localized rash – genital/perianal only (40-60%)
Minimal prodrome – mild or absent systemic symptoms
Fewer lesions – 1-10 lesions common
Rectal symptoms – proctitis, tenesmus, bleeding
Oral lesions – throat pain, difficulty swallowing

Diagnostic Methods

Clinical Diagnosis

Diagnostic Criteria:

Compatible symptoms – fever, rash, lymphadenopathy
Epidemiological risk – exposure within 21 days
Characteristic lesions – typical appearance and evolution
Exclusion of other causes – varicella, herpes, syphilis

Laboratory Testing

Test Method	Specimen Type	Sensitivity	Turnaround Time
PCR (preferred)	Lesion swab/crust	95-100%	24-48 hours
Viral culture	Lesion material	70-90%	5-7 days
Electron microscopy	Lesion fluid	80-90%	24 hours
Antigen detection	Lesion material	70-85%	2-4 hours
Serology	Blood	Variable	1-3 days

Specimen Collection

Preferred Specimens:

Vesicular fluid – highest viral load
Pustular fluid – good viral yield
Dried scabs – stable, transportable
Throat swabs – if oral lesions present

Collection Technique:

Aseptic technique – prevent contamination
Multiple lesions – increase diagnostic yield
Proper transport – viral transport medium
Chain of custody – laboratory requirements

Treatment and Management

Supportive Care

Symptom Management:

Pain control – analgesics, topical anesthetics
Fever reduction – acetaminophen, ibuprofen
Hydration – maintain fluid balance
Wound care – prevent secondary infection
Isolation – prevent transmission

Complications Management:

Secondary bacterial infection – antibiotic therapy
Proctitis – pain management, stool softeners
Ocular involvement – ophthalmologic consultation
Respiratory symptoms – supportive care

Antiviral Therapy

Medication	Indication	Dosage	Evidence
Tecovirimat (TPOXX)	Severe disease	600mg BD × 14 days	Limited clinical data
Brincidofovir	Severe/immunocompromised	100mg weekly × 2 weeks	Case reports
Cidofovir	Severe refractory cases	5mg/kg weekly	Experimental

Treatment Indications:

Severe disease – extensive lesions, systemic illness
Immunocompromised patients – high complication risk
Complications – encephalitis, pneumonia, sepsis
High-risk patients – pregnancy, children <8 years

Isolation and Infection Control

Isolation Requirements:

Duration – until all scabs have fallen off
Contact precautions – gloves, gowns
Respiratory precautions – if respiratory symptoms
Environmental cleaning – disinfection protocols

Home Isolation:

Separate room – if possible
Avoid contact – with household members
Cover lesions – clothing, bandages
Hand hygiene – frequent handwashing
Laundry precautions – separate washing

Vaccination

Vaccine Types

Vaccine	Type	Efficacy	Availability
JYNNEOS	Live, non-replicating	85% (2 doses)	Limited supply
ACAM2000	Live, replicating	85% (historical)	Research/military

Vaccination Strategies

Pre-Exposure Prophylaxis (PrEP):

High-risk individuals – MSM with multiple partners
Healthcare workers – patient care exposure
Laboratory personnel – mpox specimen handling
Close contacts – household, sexual partners

Post-Exposure Prophylaxis (PEP):

Within 4 days – optimal window for prevention
4-14 days – may reduce severity
High-risk exposures – unprotected sexual contact
Healthcare exposures – needlestick, mucous membrane

Vaccination Schedule

JYNNEOS (Imvamune):

Dose 1 – baseline
Dose 2 – 28 days later
Route – subcutaneous
Site – upper arm

Special Considerations:

Immunocompromised – may need additional doses
Pregnancy – risk-benefit assessment
Breastfeeding – generally avoided
Contraindications – severe allergy to components

Prevention Strategies

Primary Prevention

Individual Measures:

Avoid close contact – with suspected cases
Safe sexual practices – reduce transmission risk
Hand hygiene – frequent washing
Avoid sharing – personal items, bedding
Vaccination – if eligible

Community Measures:

Contact tracing – identify exposures
Public health messaging – awareness campaigns
Vaccination programs – targeted populations
Healthcare preparedness – diagnostic capacity

Secondary Prevention

Case Management:

Early isolation – prevent transmission
Contact tracing – identify and monitor contacts
Post-exposure prophylaxis – vaccination
Partner notification – sexual and close contacts

Outbreak Control:

Surveillance – monitor disease spread
Testing capacity – diagnostic availability
Vaccine allocation – priority populations
Public communication – accurate information

Special Populations

Immunocompromised Patients

Increased Risk:

HIV infection – especially low CD4 counts
Transplant recipients – immunosuppressive therapy
Cancer patients – chemotherapy effects
Primary immunodeficiencies – genetic disorders

Management Modifications:

Antiviral therapy – lower threshold for treatment
Extended isolation – prolonged viral shedding
Specialist consultation – infectious disease
Immune reconstitution – optimize immune function

Pregnancy

Maternal Risks:

Severe disease – increased complications
Fetal transmission – vertical transmission possible
Pregnancy complications – preterm labor, fetal loss
Delivery complications – transmission to newborn

Management Approach:

Antiviral therapy – consider for severe disease
Isolation precautions – prevent transmission
Fetal monitoring – assess fetal well-being
Delivery planning – cesarean section if active lesions

Pediatric Considerations

Clinical Presentation:

More severe disease – children <8 years
Respiratory involvement – pneumonia risk
Neurological complications – encephalitis
Secondary bacterial infections – common

Treatment Considerations:

Antiviral therapy – age-appropriate dosing
Supportive care – hydration, nutrition
Complication monitoring – close observation
Family education – isolation, care practices

Complications and Sequelae

Acute Complications

Complication	Frequency	Risk Factors	Management
Secondary bacterial infection	10-20%	Scratching, poor hygiene	Antibiotic therapy
Pneumonia	5-10%	Respiratory lesions	Supportive care
Encephalitis	<1%	Immunocompromised	Antiviral therapy
Keratitis	1-2%	Ocular lesions	Ophthalmologic care
Proctitis	15-30%	Rectal lesions	Symptomatic treatment

Long-term Sequelae

Dermatologic:

Scarring – permanent skin changes
Hyperpigmentation – post-inflammatory changes
Hypopigmentation – loss of skin color
Keloid formation – hypertrophic scarring

Psychological:

Anxiety – about appearance, transmission
Depression – social isolation effects
Stigma – discrimination concerns
Sexual dysfunction – fear, trauma

Public Health Response

Surveillance and Reporting

Case Definition:

Suspected – compatible illness with epidemiologic risk
Probable – suspected case with laboratory evidence
Confirmed – PCR-confirmed monkeypox virus

Reporting Requirements:

Immediate notification – within 24 hours
Case investigation – detailed epidemiologic data
Contact tracing – identify and monitor contacts
Laboratory confirmation – specimens for testing

Outbreak Management

Response Activities:

Case identification – enhanced surveillance
Contact tracing – comprehensive investigation
Vaccination campaigns – targeted populations
Public communication – risk communication

International Coordination:

WHO collaboration – global surveillance
Data sharing – epidemiologic information
Vaccine sharing – international cooperation
Travel health – border screening considerations

Innovation and Research

Therapeutic Development

New Antivirals:

Mechanism diversity – different targets
Oral formulations – improved accessibility
Combination therapy – synergistic effects
Resistance monitoring – surveillance programs

Vaccine Research:

Next-generation vaccines – improved efficacy
Intradermal delivery – dose-sparing strategies
Mucosal vaccines – enhanced protection
Variant-specific vaccines – targeted approaches

Diagnostic Advances

Rapid Testing:

Point-of-care PCR – same-visit results
Antigen detection – rapid screening
Smartphone apps – image recognition
Multiplex panels – comprehensive testing

Digital Health:

Telemedicine – remote consultation
Contact tracing apps – exposure notification
Symptom tracking – digital monitoring
AI-assisted diagnosis – pattern recognition

Health Hub Springfield Lakes: Expert Mpox Care

Comprehensive Testing Services

PCR testing – rapid, accurate diagnosis
Specimen collection – proper technique and handling
Contact tracing – comprehensive exposure assessment
Results notification – confidential communication

Vaccination Services

Risk assessment – eligibility evaluation
Pre-exposure prophylaxis – high-risk individuals
Post-exposure prophylaxis – contact management
Vaccine counseling – informed decision-making

Treatment and Management

Clinical assessment – expert evaluation
Antiviral therapy – when indicated
Supportive care – symptom management
Isolation guidance – prevent transmission

Public Health Coordination

Notification requirements – regulatory compliance
Contact tracing – public health collaboration
Outbreak response – community protection
Education programs – awareness and prevention

Book Your Mpox Consultation

Online booking: Available 24/7 at healthhubspringfieldlakes.com.au/
Phone booking: Call +61 7 3778 4888
Urgent appointments: Same-day availability for suspected cases
Confidential service: Private, non-judgmental care
Expert management: Comprehensive mpox care

Address: 18 Springfield Lakes Blvd, Springfield Lakes QLD 4300
Your trusted partner for comprehensive monkeypox testing, treatment, and prevention.

Medical References

Australian Government Department of Health. Monkeypox (mpox) – Information for Health Professionals. Commonwealth of Australia; 2024.
World Health Organization. Clinical management and infection prevention and control for monkeypox: interim rapid response guidance. Geneva: WHO; 2022.
Centers for Disease Control and Prevention. Mpox (Monkeypox) Clinical Recognition. Atlanta: CDC; 2024.
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine. Monkeypox Clinical Guidelines. Sydney: ASHM; 2023.
European Centre for Disease Prevention and Control. Monkeypox multi-country outbreak. Stockholm: ECDC; 2024.

Medical Disclaimer: This information is for educational purposes and does not replace professional medical advice. Monkeypox requires proper medical evaluation and public health management. If you have symptoms or exposure concerns, please consult a healthcare professional immediately.